Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02735707
Recruitment Status : Recruiting
First Posted : April 13, 2016
Last Update Posted : October 12, 2020
Sponsor:
Collaborators:
Australian and New Zealand Intensive Care Research Centre
Medical Research Institute of New Zealand
Unity Health
Berry Consultants
Global Coalition for Adaptive Research
University of Pittsburgh Medical Center
Information provided by (Responsible Party):
MJM Bonten, UMC Utrecht

Brief Summary:

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.


Condition or disease Intervention/treatment Phase
Community-acquired Pneumonia, Influenza, COVID-19 Drug: Fixed-duration Hydrocortisone Drug: Shock-dependent hydrocortisone Drug: Ceftriaxone Drug: Moxifloxacin or Levofloxacin Drug: Piperacillin-tazobactam Drug: Ceftaroline Drug: Amoxicillin-clavulanate Drug: Macrolide administered for 3-5 days Drug: Macrolide administered for up to 14 days Drug: Five-days oseltamivir Drug: Ten-days oseltamivir Drug: Lopinavir/ritonavir Drug: Hydroxychloroquine Drug: Hydroxychloroquine + lopinavir/ritonavir Drug: Interferon-β1a Drug: Anakinra Drug: Fixed-duration higher dose Hydrocortisone Drug: Tocilizumab Drug: Sarilumab Drug: Vitamin C Drug: Therapeutic anticoagulation Drug: Simvastatin Biological: Convalescent plasma Other: Protocolised mechanical ventilation strategy Drug: Eritoran Drug: Apremilast Drug: Aspirin Drug: Clopidogrel Drug: Prasugrel Drug: Ticagrelor Phase 4

Detailed Description:

Community-acquired pneumonia (CAP) that is of sufficient severity to require admission to an intensive care unit (ICU) is associated with substantial mortality.

Patients with pneumonia who are being treated in an ICU will receive therapy that consists of many different treatments, as many as 20 or 30. These treatments act together to treat both the infection and its effects on the body. When treating a patient, doctors choose from many different treatments, most of which are known or believed to be safe and effective. However, doctors don't always know which treatment option is the better one, as individuals or groups of individuals may respond differently. This study aims to help doctors understand which treatments work best.

This clinical study has been designed in a way that allows the information from patients already in the study to help new patients joining the study. Most studies aren't able to do that. REMAP-CAP has been designed to:

  • Evaluate multiple treatment strategies, at the same time, in the same patient.
  • Reach platform conclusions when sufficient data is accrued, rather than when a pre-specified sample size is reached
  • Utilise data that is already accrued to increase the likelihood that patients within the trial are randomised to treatments that are more likely to be beneficial
  • New questions can be substituted into the trial as initial questions are answered, meaning that the trial can be perpetual or open-ended
  • Interactions between interventions in different domains can be evaluated

It is reasonable to presume that any pandemic respiratory infection of major significance to public health will manifest as life-threatening respiratory infection including Severe Acute Respiratory illness and severe Community Acquired Pneumonia (CAP) with concomitant admission to hospital, and for some patients, admission to an Intensive Care Unit (ICU). Previous pandemics and more localized outbreaks of respiratory emerging infections have resulted in severe CAP and ICU admission.

Previous pandemics and outbreaks of emerging infectious diseases have outlined the urgent need for evidence, preferably from Randomized Controlled Trials (RCTs), to guide best treatment. However, there are substantial challenges associated with being able to organize such trials when the time of onset of a pandemic and its exact nature are unpredictable. As an adaptive platform trial that enrolls patients during the interpandemic period, REMAP-CAP is ideally positioned to adapt, in the event of a respiratory pandemic, to evaluate existing treatments as well as novel approaches.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 7100 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Actual Study Start Date : April 11, 2016
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arm Intervention/treatment
Active Comparator: Corticosteroid Domain: fixed-duration Hydrocortisone
The patient will receive IV Hydrocortisone 50 mg every 6 hours for up to 7 days.
Drug: Fixed-duration Hydrocortisone
50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.

No Intervention: Corticosteroid Domain:No systemic corticosteroid (no placebo)
The patient will receive no systemic corticosteroid for the treatment of CAP or its direct complications, up until study day 28.
Active Comparator: Corticosteroid Domain: shock dependant Hydrocortisone
The patient will receive hydrocortisone (50mg IV every 6 hours) while the patient is in septic shock.
Drug: Shock-dependent hydrocortisone
Patient will receive 50mg IV hydrocortisone every 6 hours while the patient is in septic shock

Active Comparator: Antibiotic Domain: Ceftriaxone + Macrolide
Ceftriaxone and site preferred macrolide will be administered for empiric antibiotic therapy
Drug: Ceftriaxone
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Active Comparator: Antibiotic Domain: Moxifloxacin or Levofloxacin
Moxifloxacin or levofloxacin will be administered for empiric antibiotic therapy
Drug: Moxifloxacin or Levofloxacin
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Active Comparator: Antibiotic Domain: Piperacillin-tazobactam + Macrolide
Piperacillin-tazobactam and site preferred macrolide will be administered for empiric antibiotic therapy
Drug: Piperacillin-tazobactam
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Active Comparator: Antibiotic Domain: Ceftaroline + Macrolide
Ceftaroline and site preferred macrolide will be administered for empiric antibiotic therapy
Drug: Ceftaroline

The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Ceftaroline is not available at commencement


Active Comparator: Antibiotic Domain: Amoxicillin-clavulanate + Macrolide
Amoxicillin-clavunate and site preferred macrolide will be administered for empiric antibiotic therapy
Drug: Amoxicillin-clavulanate
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Active Comparator: Macrolide Duration Domain: Standard course macrolide
The patient will receive macrolide therapy for 3-5 days. This arm is nested within the Antibiotic Domain.
Drug: Macrolide administered for 3-5 days

Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.

The dosing of and route of administration is not protocolised, the following guidance is provided:

  • Initial IV administration of a macrolide is strongly preferred
  • The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
  • The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Other Name: Standard course macrolide

Active Comparator: Macrolide Duration Domain: Extended course macrolide
The patient will receive macrolide therapy for up to 14 days. This arm is nested within the Antibiotic Domain.
Drug: Macrolide administered for up to 14 days

Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).

The dosing of and route of administration is not protocolised, the following guidance is provided:

  • Initial IV administration of a macrolide is strongly preferred
  • The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
  • The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Other Name: Extended course macrolide

No Intervention: No antiviral agent active against influenza (no placebo)
The patient will receive no antiviral agent active against influenza, including oseltamivir.
Active Comparator: Five-day course of Oseltamivir
The patient will receive a five-day course of oseltamivir.
Drug: Five-days oseltamivir
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)

Active Comparator: 10-day course of oseltamivir
The patient will receive a ten-day course of oseltamivir.
Drug: Ten-days oseltamivir
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)

No Intervention: No antiviral for COVID-19
The patient will receive no antiviral agent intended to be active against SARS-CoV-2 infection.
Active Comparator: Lopinavir/ritonavir for COVID-19
Patients will receive lopinavir/ritonavir (kaletra) 400/100mg enterally every 12 hours intended to be active against SARS-CoV-2 infection.
Drug: Lopinavir/ritonavir
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.
Other Name: Kaletra

Active Comparator: Hydroxychloroquine for COVID-19
Patients will receive hydroxychloroquine intended to be active against SARS-CoV-2 infection.
Drug: Hydroxychloroquine
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).

Active Comparator: Hydroxychloroquine + lopinavir/ritonavir for COVID-19
Patients will receive both hydroxychloroquine and lopinavir/ritonavir intended to be active against SARS-CoV-2 infection.
Drug: Hydroxychloroquine + lopinavir/ritonavir

Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.

Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).


No Intervention: No immune modulation for COVID-19
Patients will not receive any immune modulating therapy intended to be active against COVID-19.
Active Comparator: Interferon-β1a for COVID-19
Patients will receive Interferon-β1a intended to be active against COVID-19.
Drug: Interferon-β1a
IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.
Other Name: IFN-β1a

Active Comparator: Anakinra (interleukin-1 receptor antagonist) for COVID-19
Patients will receive anakinra intended to be active against COVID-19.
Drug: Anakinra

A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered very 6 hours.

In patients with renal impairment, anakinra will be administered on alternate days.

Other Name: Interleukin-1 receptor antagonist (IL-1Ra)

Active Comparator: Fixed-duration higher dose Hydrocortisone
The patient will receive IV Hydrocortisone 100mg every 6 hours for up to 7 days.
Drug: Fixed-duration higher dose Hydrocortisone
100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.

Active Comparator: Tocilizumab
Patients will receive Tocilizumab intended to be active against COVID-19
Drug: Tocilizumab

Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.

Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.


Active Comparator: Sarilumab
Patients will receive Sarilumab intended to be active against COVID-19
Drug: Sarilumab
Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.

No Intervention: No Vitamin C
Patients will not receive vitamin c (no placebo)
Active Comparator: Vitamin C
Patients will receive IV Vitamin C (50mg/kg every 6 hours for 16 doses)
Drug: Vitamin C
Vitamin C 50mg/kg administered IV every 6 hours for 16 doses

No Intervention: Standard Care Thromboprophylaxis
Patients will receive local standard care thromboprophylaxis for 14 days.
Active Comparator: Therapeutic Anticoagulation
Therapeutic anticoagulation with IV unfractionated heparin or subcutaneous low molecular weight heparin.
Drug: Therapeutic anticoagulation
Patients will be administered either low molecular weight heparin or unfractionated heparin to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.

No Intervention: No simvastatin
Patients will not receive simvastatin for up to 28 days while the patient remains in hospital.
Active Comparator: Simvastatin
Patients will receive simvastatin (80mg enterally once daily) for up to 28 days while the patient remains in hospital.
Drug: Simvastatin
Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation

No Intervention: No immunoglobulin against SARS-CoV-2
Patients will not receive any preparation of immunoglobulin intended to neutralise SARS-CoV-2 during the index hospitalisation.
Active Comparator: Convalescent plasma
Patients will receive at least one, and not more than two, units of convalescent plasma within 48 hours of randomisation.
Biological: Convalescent plasma
Patients will recieve at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.

No Intervention: Clinician-preferred invasive ventilation
Patients will receive invasive mechanical ventilation as determined by the treating clinician.
Active Comparator: Protocolised invasive mechanical ventilation strategy
Patient will receive a protocolised invasive mechanical ventilation strategy
Other: Protocolised mechanical ventilation strategy
See Domain Specific Appendix for a complete description of protoclised invasive mechanical ventilation strategy.

Active Comparator: Eritoran
Patients will receive Eritoran intended to be active against COVID-19
Drug: Eritoran
Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital

Active Comparator: Apremilast
Patients will receive Apremilast intended to be active against COVID-19
Drug: Apremilast
Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.

No Intervention: No antiplatelet
Patients will not receive any antiplatelet agent or NSAID for 14 days while patient remains in hospital
Active Comparator: Aspirin
Patients will receive aspirin for up to 14 days while the patient remains in hospital
Drug: Aspirin
Aspiring administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.
Other Name: acetylsalicylic acid

Active Comparator: P2Y12 inhibitor
Patients will receive either clopidogrel, prasugrel, or ticagrelor (as per site preference).
Drug: Clopidogrel
Clopidogrel administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.

Drug: Prasugrel

If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.

If patient's age is more than 75 years, or measured or estimated weight is less than 60kg, an initial loading dose of 60mg will be administered, followed by 5mg per day.

Prasugrel will be administered for 14 days or until hospital discharge, whichever occurs first.


Drug: Ticagrelor
Ticagrelor administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.




Primary Outcome Measures :
  1. All-cause mortality [ Time Frame: Day 90 ]
  2. Days alive and not receiving organ support in ICU [ Time Frame: Day 21 ]
    Primary end-point for patients with suspected or proven COVID-19 pandemic infection


Secondary Outcome Measures :
  1. ICU Mortality [ Time Frame: Day 90 ]
  2. ICU length of stay [ Time Frame: Day 90 ]
  3. Hospital length of stay [ Time Frame: Day 90 ]
  4. Ventilator free days [ Time Frame: Day 28 ]
  5. Organ failure free days [ Time Frame: Day 28 ]
  6. All-cause mortality [ Time Frame: 6 months ]
  7. Health-related Quality of life assessment [ Time Frame: 6 months ]
    EQ5D-5L and WHODAS 2.0 (not completed in all regions)

  8. Proportion of intubated patients who receive a tracheostomy [ Time Frame: Day 28 ]
  9. Destination at time of hospital discharge [ Time Frame: Free text Day 90 ]
    Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital

  10. Readmission to the index ICU during the index hospitalization [ Time Frame: Day 90 ]
  11. World Health Organisation 8-point ordinal scale outcome [ Time Frame: Hospital discharge ]

Other Outcome Measures:
  1. Occurrence of multi-resistant organism colonisation/infection [ Time Frame: Day 90, censored at hospital discharge ]
    Antibiotic Domain specific outcome

  2. Occurrence clostridium difficile [ Time Frame: Day 90, censored at hospital discharge ]
    Antibiotic Domain specific outcome

  3. Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death [ Time Frame: Day 90, censored at hospital discharge ]
    Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.

  4. Change from baseline influenza virus levels in upper and lower respiratory tract specimens [ Time Frame: Day 3, up to Day 7 ]
    Antiviral Domain specific outcome. Only required at selected sites.

  5. Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing) [ Time Frame: Day 90, censored at hospital discharge ]
    COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

REMAP-CAP PLATFORM INCLUSION CRITERIA:

  1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:

    1. symptoms or signs or both that are consistent with lower respiratory tract infection AND
    2. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
  2. Up to 48 hours after ICU admission, receiving organ support with one or more of:

    1. Non-invasive or Invasive ventilatory support;
    2. Receiving infusion of vasopressor or inotropes or both

PLATFORM EXCLUSION CRITERIA:

  1. Healthcare-associated pneumonia:

    1. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
    2. Resident of a nursing home or long term care facility
  2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
  3. Previous participation in this REMAP within the last 90 days

REMAP-COVID PLATFORM INCLUSION CRITERIA

1. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection.

REMAP-COVID PLATFORM EXCLUSION CRITERIA

  1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
  2. Patient is expected to be discharged from hospital today or tomorrow
  3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection.
  4. Previous participation in this REMAP within the last 90 days

DOMAIN-SPECIFIC ELIGIBLE CRITERIA:

Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02735707


Contacts
Layout table for location contacts
Contact: Cameron Green info@remapcap.org
Contact: Wilma Van Bentum-Puijk, MSc +31 (0) 88 755 5555 prepare_icu@umcutrecht.nl

Locations
Show Show 90 study locations
Sponsors and Collaborators
MJM Bonten
Australian and New Zealand Intensive Care Research Centre
Medical Research Institute of New Zealand
Unity Health
Berry Consultants
Global Coalition for Adaptive Research
University of Pittsburgh Medical Center
Investigators
Layout table for investigator information
Study Chair: Steve Webb, Prof Monash University, Study Chair REMAP-CAP Australia
Study Chair: Colin McArthur, Dr Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand
Study Chair: Marc Bonten, Prof UMC Utrecht, Study Chair REMAP-CAP Europe
Study Chair: Lennie Derde, MD UMC Utrecht, Coordinating Investigator REMAP-CAP Europe
Study Chair: Marshall Marshall, Prof Unity Health Toronto
Study Chair: Angus Derek, Prof University of Pittsburgh Medical Center
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Writing Committee for the REMAP-CAP Investigators, Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Buzgau A, Cheng AC, de Jong M, Detry M, Estcourt L, Fitzgerald M, Goossens H, Green C, Haniffa R, Higgins AM, Horvat C, Hullegie SJ, Kruger P, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, Marshall J, McAuley D, McGlothin A, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Rowan K, Sanil A, Santos M, Saunders C, Seymour C, Turner A, van de Veerdonk F, Venkatesh B, Zarychanski R, Berry S, Lewis RJ, McArthur C, Webb SA, Gordon AC. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 Sep 2. doi: 10.1001/jama.2020.17022. [Epub ahead of print]

Layout table for additonal information
Responsible Party: MJM Bonten, Prof. Medical Microbiology, UMC Utrecht
ClinicalTrials.gov Identifier: NCT02735707    
Other Study ID Numbers: U1111-1189-1653
2015-002340-14 ( EudraCT Number )
602525 ( Other Grant/Funding Number: European Union, FP7-HEALTH-2013-INNOVATION-1, PREPARE )
16/631 ( Other Grant/Funding Number: Platform Trial Optimising Interventions in Severe Community Acquired Pneumonia Health Research Council, New Zealand) )
APP1101719 ( Other Grant/Funding Number: OPTIMISE-CAP, The National Health and Medical Research Council, Australia )
158584 ( Other Grant/Funding Number: Canadian Institute of Health Research, Strategy for Patient-Oriented Research (CIHR- )
First Posted: April 13, 2016    Key Record Dates
Last Update Posted: October 12, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by MJM Bonten, UMC Utrecht:
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Anti-Bacterial Agents
Moxifloxacin
Levofloxacin
Antibiotics
Hydrocortisone
Anti-Infective Agents
Ceftriaxone
Piperacillin-tazobactam
Ceftaroline
Amoxicillin-clavulanate
Oseltamivir
COVID-19
Influenza
Intensive care
Critical care
SARS-CoV-2
Vitamin C
Therapeutic Anticoagulation
Statin
Invasive Mechanical Ventilation
Convalescent plasma
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Respiratory Tract Infections
Respiratory Tract Diseases
Lung Diseases
Aspirin
Interferons
Ritonavir
Lopinavir
Oseltamivir
Interferon-beta
Interferon beta-1a
Amoxicillin
Moxifloxacin
Hydroxychloroquine
Levofloxacin
Tazobactam
Ceftriaxone
Piperacillin
Clavulanic Acid
Ceftaroline fosamil
Piperacillin, Tazobactam Drug Combination
Amoxicillin-Potassium Clavulanate Combination
Apremilast
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Interleukin 1 Receptor Antagonist Protein
Clopidogrel
Ticagrelor